Fig. 1: Study consort diagram.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
CONSORT flowchart illustrating patient disposition throughout the study.
Fig. 1: Study consort diagram. | Nature Medicine
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
CONSORT flowchart illustrating patient disposition throughout the study.